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Results: For dataset A, n = 9213 and B, n = 1244. The most fre-
quently dispensed antidepressant was amitriptyline (A: 67.75%, 
n = 6242; B: 64.06%, n = 797). The mean age of patients was 43.86 
(13.81) and 46.27 (13.07), respectively. The type of antidepressant 
used was significantly associated with ICD-10 code, psychiatric 
condition, and categorical age (P < 0.0001). The mean number of 
antidepressant prescriptions per patient were: A, 2.95 (3.77); and B, 
2.57 (2.47). Duration of treatment was related to age, ICD-10 code, 
and psychiatric condition (P < 0.0001).
Conclusion: Since their inception, there has been a steady increase 
in global antidepressant prescriptions, despite controversies concern-
ing efficacy and safety of these drugs. This trend is also evident in 
South Africa: This research shows that amitriptyline accounts for a 
majority of prescriptions because of its varied indications for use. 
The determinants of the type of antidepressant used showed that 
patients with a psychiatric condition were more likely to receive a 
newer antidepressant, and patients with a pain condition were more 
likely to receive an older antidepressant. These results will ultimately 
be compared with DUR data from the private and general public 
sectors of Gauteng health services to establish a baseline for making 
recommendations concerning safety, efficacy, and cost-effectiveness 
of antidepressant use in Gauteng.
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Introduction: Pregabalin, an agent in treating partial epilepsy and 
peripheral neuropathic and central pain, was studied for its effect on 
driving performance in healthy volunteers. The study was approved 
by the ethical committee of Ehime University Hospital. Written 
informed consent was obtained from the volunteers before partici-
pation in the study, which was performed in accordance with the 
principles of the Declaration of Helsinki.
Patients (or Materials) and Methods: Sixteen regularly driving, 
healthy male volunteers were enrolled for a double-blind placebo 
control study of pregablin on driving performance. Driving simulator 
was used to test the simple and complicated braking reaction time, 
simple and complicated steering wheel techniques. Pregabalin was 
also evaluated for the effect of training on driving tests.
Results: The mean (SD) age of pregabalin and placebo groups were 
26.0 (2.9) and 28.6 (3.5) years, respectively. The body weight, plasma 
creatinine level, and eGFR of pregabalin group were 69.0 (4.7) kg, 
0.8 (0.04) mg/dL, and 94.1 (5.7) mL/min, respectively. The body 
weight, plasma creatinine level, and eGFR of placebo group were 
62.16 (4.6) kg, 0.8 (0.05) mg/dL, and 96.7 (6.5) mL/min, respectively. 
Six members of the pregabalin group and 2 members of placebo 
group reported sleepiness. The other 2 members of the pregabalin 
group presented somnolence during driving. All the subjects showed 
no serious adverse effects. There were no significant differences of 
both simple and complicated braking reaction time between pregaba-
lin and placebo groups. The simple and complicated wheel techniques 
also showed no differences between pregabalin and placebo groups. 
In comparing the effect of training on the driving performance, the 
placebo group showed the improvement in the test of simple steering 
wheel technique. The number of errors in handling wheel detected 1 
hour and 2 hours from the baseline showed significantly reduction 
compared with the baseline data. However, the pregabalin group 
showed no improvement in handling wheels with the training. Both 
pregabalin and placebo groups had no changes in both simple and 
complicated braking reaction time, and complicated handling wheel 
tests.
Conclusion: In our study using driving simulator, pregablin exhibited 
no serious central nervous system side effects in engaging driving, but 
caused mild effects to decrease the training of driving.
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Introduction: To calculate the incidence, describe the suspected cases 
of paracetamol poisoning, and determine the differences between the 
patterns of acute versus chronic ingestion in patients < 18 years of 
age who were treated at a tertiary hospital.
Patients (or Materials) and Methods: Retrospective cohort study 
of patients < 18 years of age who were treated in the emergency 
department (pediatric and general) of the La Paz University Hospital 
for suspected paracetamol intoxication and for whom paracetamol 
serum level tests were requested.
Results: Ninety-two (92) patients with suspected paracetamol 
poisoning were identified between 2005 and 2010. The incidence 
for 2007 was 1.53 cases (95% CI Poisson, 0.24–5.57) per 10,000 
patients treated at the pediatric emergency department. The most 
common cause of poisoning was attempted suicide (47.8%), with a 
median age of 15 years, followed by accidental poisoning (42.2%), 
with a median age of 2.65 years. Following the assessment of causal-
ity, we found that 1 patient with acute poisoning showed a hepatic 
disorder secondary to paracetamol, while 7 of the 11 patients with 
chronic poisoning showed liver enzyme disorders secondary to par-
acetamol poisoning. The time required to find medical care was 6.83 
hours for acute poisoning and 52.3 hours for chronic poisoning 
(P < 0.001).
Conclusion: Chronic paracetamol poisoning is a potential risk factor 
for hepatotoxicity and ALF; delays in seeking medical help may be a 
contributing factor. The parents/guardians should therefore be noti-
fied of this fact, and the ED physicians’ clinical suspicion increased.
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Introduction: Misuses of buprenorphine concern ~30% of patients 
treated for drug detoxification in cases of opioid abuse. Injecting pills 
that are not intended for intravenous (IV) administration may have 
harmful consequences, particularly because of particles. The main 
difference between Subutex® and its generics concern the insoluble 
